| Name | calcium channel (protein family or complex) |
|---|---|
| Synonyms | calcium channel |
| Name | biphenyl |
|---|---|
| CAS | 1,1′-biphenyl |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18391092 | Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L: Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, and Hypertension. 2008 May;51(5):1306-11. Epub 2008 Apr 7. Mice were treated with aliskiren (renin inhibitor), irbesartan (angiotensin-receptor blocker), (beta-blocker), or (calcium channel blocker). |
2(0,0,0,2) | Details |
| 19601700 | Bramlage P, Durand-Zaleski I, Desai N, Pirk O, Hacker C: The value of irbesartan in the management of hypertension. . Expert Opin Pharmacother. 2009 Aug;10(11):1817-31. Angiotensin receptor blockers (ARBs) have demonstrated a blood pressure lowering efficacy which is at least comparable with other drug classes, including ACE inhibitors (ACE-I), beta-blockers, calcium channel blockers and diuretics. |
2(0,0,0,2) | Details |
| 18816587 | Choe YJ, Seo HN, Jung SY, Rhim H, Kim J, Choo DJ, Lee JY: Synthesis and SAR study of T-type calcium channel blockers. Arch Pharm. 2008 Oct;341(10):661-4. It was revealed that a 5-(dimethylamino) pentylamino group at R (1), a biphenyl group at R (2), and a benzyl amido group at R (3) in the 3,4-dihydroquinazoline backbone are closely related with the channel selectivity (T/N-type) as well as the potency based on the discovery of 6k (KYS05090). |
2(0,0,0,2) | Details |
| 18434751 | Busch M, Franke S, Wolf G, Rohde RD, Stein G: Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract. 2008;108(4):c291-7. Epub 2008 Apr 24. METHODS: One hundred and ninety-six patients of the Irbesartan in Diabetic Nephropathy Trial cohort (mean age 61 +/- 6.5 years, 62 female, 134 male) with a mean estimated glomerular filtration rate of 47.7 ml/min were treated with irbesartan (n = 65), the calcium channel blocker (n = 61) or by placebo (n = 70). |
1(0,0,0,1) | Details |
| 18279770 | McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM: Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008 Feb;10(2):149-56. The following treatments were used at baseline: diuretic 83%, beta-blocker 59%, calcium channel blocker 40%, ACE inhibitor 25%, spironolactone 15% and 14%. |
1(0,0,0,1) | Details |
| 17877649 | Palmer AJ, Valentine WJ, Ray JA: Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. Int J Clin Pract. 2007 Oct;61(10):1626-33. Three treatment strategies were evaluated: (i) 'control' regimen of conventional antihypertensive therapy (excluding angiotensin-converting enzyme inhibitors, angiotensin-2-receptor antagonists and dihydropyridine calcium-channel blockers), (ii) 'early irbesartan' 300 mg daily and (iii) 'late irbesartan' 300 mg daily (started when overt nephropathy developed). |
1(0,0,0,1) | Details |
| 20066707 | Wetzel A, Pratsch G, Kolb R, Heinrich MR: Radical arylation of phenols, phenyl ethers, and furans. Chemistry. 2010 Feb 22;16(8):2547-56. The methodology described offers a fast, efficient, and cost-effective new access to diversely functionalized biphenyl and ethers. Two examples for the applicability of the methodology are the partial synthesis of a beta-secretase inhibitor and the synthesis of a calcium-channel modulator. |
1(0,0,0,1) | Details |